| 2026 Consensus Statement Update | 2022 Consensus Statement |
|---|---|
| Scenario 4 Patients with recurrence during adjuvant T-DM1 (non-pCR after neoadjuvant treatment), or relapse within 6 months after the end of adjuvant T-DM1: T-DXd with or without pertuzumab and tucatinib/trastuzumab/capecitabine are both treatment options. If neoadjuvant pertuzumab has not been used, chemotherapy/trastuzumab/pertuzumab (IV or SC) is also an option. | Scenario 3 Patients with recurrence during adjuvant T-DM1 (non-pCR after neoadjuvant treatment), or relapse within 6 months after the end of adjuvant T-DM1: • When trastuzumab plus pertuzumab has been used in neoadjuvant setting: trastuzumab deruxtecan and tucatinib/trastuzumab/capecitabine are the preferred 1 and 2 line treatment, but the optimal sequencing is unclear. |
References
DB-02, HER2CLIMB
Quality of evidence: II; Strength of recommendation: B